Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
- PMID: 38637885
- PMCID: PMC11025286
- DOI: 10.1186/s12967-024-05174-y
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
Abstract
Background: Ovarian cancer (OC) is characterized by its rapid growth and spread which, accompanied by a low 5-year survival rate, necessitates the development of improved treatments. In ovarian cancer, the selective overexpression of Mucin-16 (MUC16, CA125) in tumor cells highlights its potential as a promising target for developing anti-tumor therapies. However, the potential effectiveness of CAR-T cell therapy that targets MUC16 in ovarian cancer cells is unknown.
Methods: The expression of MUC16 in viable OC cells was detected using immunofluorescence and flow cytometry techniques. A MSLN-CAR construct, comprising the MUC16-binding polypeptide region of mesothelin (MSLN), a CD8 hinge spacer and transmembrane domain, 4-1BB, and CD3ζ endo-domains; was synthesized and introduced into T cells using lentiviral particles. The cytotoxicity of the resultant CAR-T cells was evaluated in vitro using luciferase assays. Cytokine release by CAR-T cells was measured using enzyme-linked immunosorbent assays. The anti-tumor efficacy of the CAR-T cells was subsequently assessed in mice through both systemic and local administration protocols.
Results: MSLN-CAR T cells exhibited potent cytotoxicity towards OVCAR3 cells and their stem-like cells that express high levels of MUC16. Also, MSLN-CAR T cells were inefficient at killing SKOV3 cells that express low levels of MUC16, but were potently cytotoxic to such cells overexpressing MUC16. Moreover, MSLN-CAR T cells delivered via tail vein or peritoneal injection could shrink OVCAR3 xenograft tumors in vivo, with sustained remission observed following peritoneal delivery of MSLN-CAR T cells.
Conclusions: Collectively, these results suggested that MSLN-CAR T cells could potently eliminate MUC16- positive ovarian cancer tumor cells both in vitro and in vivo, thereby providing a promising therapeutic intervention for MUC16-positive patients.
Keywords: CAR-T cells; MUC16 (CA125); Mesothelin; Ovarian cancer.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no financial or non-financial competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11025286/bin/12967_2024_5174_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11025286/bin/12967_2024_5174_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11025286/bin/12967_2024_5174_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11025286/bin/12967_2024_5174_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11025286/bin/12967_2024_5174_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11025286/bin/12967_2024_5174_Fig6_HTML.gif)
Similar articles
-
Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.Expert Rev Anticancer Ther. 2018 Feb;18(2):177-186. doi: 10.1080/14737140.2018.1418326. Epub 2017 Dec 21. Expert Rev Anticancer Ther. 2018. PMID: 29241375 Review.
-
Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.Exp Cell Res. 2021 Dec 1;409(1):112886. doi: 10.1016/j.yexcr.2021.112886. Epub 2021 Oct 19. Exp Cell Res. 2021. PMID: 34673000
-
Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells.Cancer Immunol Immunother. 2024 Jul 2;73(9):163. doi: 10.1007/s00262-024-03740-3. Cancer Immunol Immunother. 2024. PMID: 38954005 Free PMC article.
-
Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.Cancer Immunol Immunother. 2023 Apr;72(4):917-928. doi: 10.1007/s00262-022-03290-6. Epub 2022 Sep 27. Cancer Immunol Immunother. 2023. PMID: 36166071 Free PMC article.
-
Mesothelin-targeted CAR-T cell therapy for solid tumors.Expert Opin Biol Ther. 2021 Apr;21(4):473-486. doi: 10.1080/14712598.2021.1843628. Epub 2020 Nov 12. Expert Opin Biol Ther. 2021. PMID: 33176519 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous